Af­ter poor lung can­cer da­ta, iTeos drops in­u­padenant to dou­ble down on TIG­IT

iTeos Ther­a­peu­tics will set aside in­u­padenant fol­low­ing lack­lus­ter mid-stage da­ta in non-small cell lung can­cer. The com­pa­ny will fo­cus on its TIG­IT ther­a­pies in­stead, with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER